39
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background and Aims

          Manual histological assessment is currently the accepted standard for diagnosing and monitoring disease progression in NASH, but is limited by variability in interpretation and insensitivity to change. Thus, there is a critical need for improved tools to assess liver pathology in order to risk stratify NASH patients and monitor treatment response.

          Approach and Results

          Here, we describe a machine learning (ML)‐based approach to liver histology assessment, which accurately characterizes disease severity and heterogeneity, and sensitively quantifies treatment response in NASH. We use samples from three randomized controlled trials to build and then validate deep convolutional neural networks to measure key histological features in NASH, including steatosis, inflammation, hepatocellular ballooning, and fibrosis. The ML‐based predictions showed strong correlations with expert pathologists and were prognostic of progression to cirrhosis and liver‐related clinical events. We developed a heterogeneity‐sensitive metric of fibrosis response, the Deep Learning Treatment Assessment Liver Fibrosis score, which measured antifibrotic treatment effects that went undetected by manual pathological staging and was concordant with histological disease progression.

          Conclusions

          Our ML method has shown reproducibility and sensitivity and was prognostic for disease progression, demonstrating the power of ML to advance our understanding of disease heterogeneity in NASH, risk stratify affected patients, and facilitate the development of therapies.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: not found
          • Conference Proceedings: not found

          Deep Residual Learning for Image Recognition

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Interrater reliability: the kappa statistic

            The kappa statistic is frequently used to test interrater reliability. The importance of rater reliability lies in the fact that it represents the extent to which the data collected in the study are correct representations of the variables measured. Measurement of the extent to which data collectors (raters) assign the same score to the same variable is called interrater reliability. While there have been a variety of methods to measure interrater reliability, traditionally it was measured as percent agreement, calculated as the number of agreement scores divided by the total number of scores. In 1960, Jacob Cohen critiqued use of percent agreement due to its inability to account for chance agreement. He introduced the Cohen’s kappa, developed to account for the possibility that raters actually guess on at least some variables due to uncertainty. Like most correlation statistics, the kappa can range from −1 to +1. While the kappa is one of the most commonly used statistics to test interrater reliability, it has limitations. Judgments about what level of kappa should be acceptable for health research are questioned. Cohen’s suggested interpretation may be too lenient for health related studies because it implies that a score as low as 0.41 might be acceptable. Kappa and percent agreement are compared, and levels for both kappa and percent agreement that should be demanded in healthcare studies are suggested.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

              Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in the absence of a history of significant alcohol use or other known liver disease. Nonalcoholic steatohepatitis (NASH) is the progressive form of NAFLD. The Pathology Committee of the NASH Clinical Research Network designed and validated a histological feature scoring system that addresses the full spectrum of lesions of NAFLD and proposed a NAFLD activity score (NAS) for use in clinical trials. The scoring system comprised 14 histological features, 4 of which were evaluated semi-quantitatively: steatosis (0-3), lobular inflammation (0-2), hepatocellular ballooning (0-2), and fibrosis (0-4). Another nine features were recorded as present or absent. An anonymized study set of 50 cases (32 from adult hepatology services, 18 from pediatric hepatology services) was assembled, coded, and circulated. For the validation study, agreement on scoring and a diagnostic categorization ("NASH," "borderline," or "not NASH") were evaluated by using weighted kappa statistics. Inter-rater agreement on adult cases was: 0.84 for fibrosis, 0.79 for steatosis, 0.56 for injury, and 0.45 for lobular inflammation. Agreement on diagnostic category was 0.61. Using multiple logistic regression, five features were independently associated with the diagnosis of NASH in adult biopsies: steatosis (P = .009), hepatocellular ballooning (P = .0001), lobular inflammation (P = .0001), fibrosis (P = .0001), and the absence of lipogranulomas (P = .001). The proposed NAS is the unweighted sum of steatosis, lobular inflammation, and hepatocellular ballooning scores. In conclusion, we present a strong scoring system and NAS for NAFLD and NASH with reasonable inter-rater reproducibility that should be useful for studies of both adults and children with any degree of NAFLD. NAS of > or =5 correlated with a diagnosis of NASH, and biopsies with scores of less than 3 were diagnosed as "not NASH."
                Bookmark

                Author and article information

                Contributors
                andy.beck@pathai.com
                Journal
                Hepatology
                Hepatology
                10.1002/(ISSN)1527-3350
                HEP
                Hepatology (Baltimore, Md.)
                John Wiley and Sons Inc. (Hoboken )
                0270-9139
                1527-3350
                24 June 2021
                July 2021
                : 74
                : 1 ( doiID: 10.1002/hep.v74.1 )
                : 133-147
                Affiliations
                [ 1 ] PathAI Boston MA
                [ 2 ] Gilead Sciences, Inc. Foster City CA
                [ 3 ] Lahey Hospital & Medical Center (Emeritus) Burlington MA
                [ 4 ] University Gastroenterology Portsmouth RI
                [ 5 ] Warren Alpert Medical School of Brown University Providence RI
                [ 6 ] Translational & Clinical Research Institute, Faculty of Medical Sciences Newcastle University Newcastle upon Tyne UK
                [ 7 ] Department of Medicine and Therapeutics The Chinese University of Hong Kong Hong Kong Hong Kong
                [ 8 ] Division of Gastroenterology and Hepatology Medical University of Vienna Vienna Austria
                [ 9 ] Texas Liver Institute UT Health San Antonio San Antonio TX
                [ 10 ] Pinnacle Clinical Research San Antonio TX
                [ 11 ] Saiseikai Suita Hospital Suita City Japan
                [ 12 ] Hospital Universitario Virgen del Rocio Sevilla Spain
                [ 13 ] Department of Medicine Inova Fairfax Medical Campus Falls Church VA
                [ 14 ] Betty and Guy Beatty Center for Integrated Research Inova Health System Falls Church VA
                [ 15 ] NAFLD Research Center University of California at San Diego La Jolla CA
                Author notes
                [*] [* ] ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:

                Andrew H. Beck, M.D., Ph.D.

                PathAI

                120 Brookline Avenue

                Boston, MA 02115

                E‐mail: andy.beck@ 123456pathai.com

                Tel.: +1‐650‐291‐5004

                Author information
                https://orcid.org/0000-0002-9518-0088
                https://orcid.org/0000-0003-2215-9410
                https://orcid.org/0000-0001-8494-8947
                https://orcid.org/0000-0002-9978-134X
                Article
                HEP31750
                10.1002/hep.31750
                8361999
                33570776
                38237a98-411c-4eef-949a-00b0fffcf3a5
                © 2021 PathAI. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 23 December 2020
                : 24 August 2020
                : 05 January 2021
                Page count
                Figures: 4, Tables: 1, Pages: 15, Words: 8590
                Funding
                Funded by: Gilead Sciences Inc. , doi 10.13039/100005564;
                Categories
                Original Article
                Original Articles
                Steatohepatitis/Metabolic Liver Disease
                Custom metadata
                2.0
                July 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.5 mode:remove_FC converted:13.08.2021

                Gastroenterology & Hepatology
                Gastroenterology & Hepatology

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content141

                Cited by72

                Most referenced authors920